NCT05244759View on ClinicalTrials.gov

Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

September 23, 2020

Study Completion Date

March 2, 2021

Conditions
Healthy
Interventions
DRUG

[14C]-BLU-5937

Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

All Listed Sponsors
lead

Bellus Health Inc. - a GSK company

INDUSTRY

NCT05244759 - Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 | Biotech Hunter | Biotech Hunter